 FibroGen, Inc.s NASDAQ: FGEN shares are sinking to their lowest level since late June 2016. FibroGens AdCom Snub FibroGen said late Thursday the Food and Drug Administrations Cardiovascular and Renal Drugs Advisory Committee met to discuss the new drug application for roxadustat, voted against approval of the drug. 